Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ghimire S, Karki S, Maharjan B, Kosterink JGW, Touw DJ, et al.
Objectives The objectives of this study were to evaluate treatment in patients on current programmatic multidrug-resistant tuberculosis (MDR-TB) regimen and verify eligibility for the 9-month regimen and therapeutic drug monitoring (TDM). Methods We performed a retrospective char…
Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, et al.
Background and aims Multi drug or rifampicin resistant tuberculosis (MDR/RR-TB) is a major burden to TB prevention and eradication globally. Since 2016, WHO guidelines have included options for treating MDR/RR-TB with a standard regimen of 9 to 11 months duration (the 'shorter re…
Garg K, Kaur K, Gupta A, Chopra V, Kumari S
Introduction The launch of injectable shorter regimens under Programmatic Management of Drug Resistant Tuberculosis (PMDT) guidelines 2017 under Revised National Tuberculosis Control Program (RNTCP) was a welcome step as it decreased the duration of treatment significantly in Dru…
liu yidian
…tohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug-resistant tuberculosis (MDR-TB). The primary objectives are to assess the safety and tolerability of AHA combined with short-course regimens, and to determine the re…
Н.В. Чумоватов, О. Г. Комиссарова, N. Chernykh, А. Э. Эргешов
…nitiated interruptions. In recent years, the use of shorter regimens for the treatment of multidrug-resistant tuberculosis has been actively discussed around the world. The first use of shorter chemotherapy regimens was conducted in three regions of the Russian Federation in 2019…
Boubacar Diallo, Alhassane Diallo, Oumou Hawa Diallo, Alpha Oumar Barry, Aboubacar Sidiki Magassouba, et al.
… with shorter oral bedaquiline-containing versus injectable regimens in Guinea. Materials and Methods: We enrolled patients with RR-TB who were treated with an MDR-TB treatment regimen from June 2016 to June 2022 in three tuberculosis (TB) centers in Guinea. The primary outcome w…
Hindol Mondal, Manasi Banerjee, Abheek Das, Somnath Maity
Introduction: Multidrug resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is a leading cause of death in India. To combat this, National TB Elimination Programme, erstwhile RNTCP) has launched “shorter oral bedaquiline (Bdq)-containing MDR/RR-TB regimen” from March 2021 rep…
Disha S. Patel, Chetankumar Acharya
Background: Tuberculosis is major cause of death in India. Analysis of heart rate variability is one of the most popular methods of autonomic nervous system evaluation. Shorter MDR-TB regimen drugs affect both central nervous system as well as peripheral nervous system. Existing …
Vivian Lofranco, Vincent M. Balanag, Lawrence O. Raymond, Noel G. Macalalad, A V Golubkov, et al.
Background: The Philippines has a burden of drug-resistant tuberculosis (DR-TB). One of the key challenges in the programmatic management of DR-TB (PMDT) is the high rate of loss to follow-up (38% in the 2010 cohort). An urgent need for a shorter, more tolerable, less expensive t…
Himanshi Khera, Tarun Narang, Seema Chhabra, Debajyoti Chhaterjee, Samir Malhotra, et al.
…pad. Groups of animals using different dosing schedules and regimens for bedaquiline are compared against WHO-MDT regimen. Additionally, drug interaction study for evaluating interaction with concomitantly administered drugs was carried out in Swiss albino mice. For clinical stud…
PrasantaKumar Das, SomtirthaB Ganguly
Background: Shorter multidrug-resistant (MDR) regimen has proved to be very effective in some of the developing nations such as Bangladesh and several African countries. Various shortcomings in the execution of long-term MDR regimen have prompted for adapting the shorter regimen …
Zeeshan Saleem, Imran Ullah, Muhammad Sarim Bin Farooq Awan, Jamal Tauqir, Faisal Younis, et al.
Background: Drug-resistant tuberculosis (DR-TB) is the major cause of mortality worldwide. Our objectives were to determine the distribution of DR-TB by sex, age groups, occupation, province, division, district, type of disease, type of drug resistance, treatment regimen and outc…
Wuhan Pulmonary Hospital
… new, effective, safe, and short-course anti-drug-resistant regimens. A 6-month short-course oral regimen containing pretomanid was launched in 2020 and was approved for marketing in China in March 2025. Currently, there have been multi-center studies on the treatment of rifampic…
Wenwen Sun, Qin Tang, Jie Wang, Jin‐Hui Yang, Fangyou Yu, et al.
Abstract Background: MDR-TB（multidrug-resistant tuberculosis） remains the challenge with low success rate of treatment. Pasiniazid had been applied in China for two decades, but relevant clinical studies are rare. To verify the efficacy and safety of a regimen containing pasiniaz…
Tack I, Dumicho A, Ohler L, Shigayeva A, Bulti AB, et al.
…the program setting. Support is needed when introducing new regimens to train staff in the monitoring, management, and reporting of AEs.
Kokebu DM, Ahmed S, Moodliar R, Chiang CY, Torrea G, et al.
BACKGROUND: STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the WHO. The present…
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.
…ts with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed. Methods We conducted an open-label, phase 2-3, multicenter, randomized, controlled, noninferiori…
Agnarson AM, Wang XC, Potluri R, Bhandari H, Dhir A, et al.
…e high drug-resistant tuberculosis (DR-TB) burden in China. Regimens including the oral agent bedaquiline have been shown to be efficacious and safe, leading to its incorporation into multiple national TB treatment programs. This analysis evaluated the impact of increased adoptio…
Yan L, Kan X, Zhu L, Xu K, Yin J, et al.
Purpose We designed a prospective, multicenter, randomized, controlled study to assess a 5-month regimen compared with the standard regimen on previously treated patients with pulmonary tuberculosis (TB). Methods We enrolled 917 sputum smear-positive patients undergoing additiona…
Min J, Kim HW, Kang JY, Kim SK, Kim JW, et al.
…erculosis notified between 2011 and 2018 in Korea. Baseline regimens were classified into two groups, namely 6-9-month rifampicin, ethambutol, and pyrazinamide (6-9REZ) and a combination regimen of 2-month rifampicin, ethambutol, pyrazinamide and 7-10-month rifampicin and ethambu…
Jihwaprani MC, Sun Y, Rizky WC, Sula I, Saquib N
…e aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceD…
Kumar GS, Sameena P, Karthik V, Ghanate N
… treatment, and 40,397 (75%) were initiated on shorter drug regimens at the time of diagnosis. In the absence of an effective vaccine, there is an urgent need for new treatment regimens, drugs, and diagnostics to slow the evolution of drug resistance and limit transmission of res…
Nida Khan, Muhammad Ahmar Khan, Naila Muzaffar, Ahmad Ismail, Abdul Ghafoor, et al.
…according to the global estimates. Novel all oral treatment regimens containing new antibiotics with reduced treatment duration are available. World Health Organization guidelines recommend the use of shorter all-oral regimens under operational research. To guide recommendations,…
Mleoh L, Mziray SR, Tsere D, Koppelaar I, Mulder C, et al.
Objective In 2018, shorter treatment regimens (STR) for people with drug-resistant tuberculosis (DR-TB) were introduced in Tanzania and included kanamycin, high-dose moxifloxacin, prothionamide, high-dose isoniazid, clofazimine, ethambutol and pyrazinamide. We describe treatment …
Doan TN, Cao P, Emeto TI, McCaw JM, McBryde ES
Short-course regimens for multidrug-resistant tuberculosis (MDR-TB) are urgently needed. Limited data suggest that the new drug bedaquiline (BDQ) may have the potential to shorten MDR-TB treatment to less than 6 months when used in conjunction with standard anti-TB drugs. However…